Multiple sclerosis is a chronic immune-mediated disease of the central nervous system in which inflammatory demyelination and neurodegeneration disrupt neural transmission and cause variable neurological disability.
Two new studies advance Lyme disease research: anti-lipid antibodies may enable earlier diagnosis and detect persistent symptoms, while cell wall changes in Borrelia burgdorferi offer insights into Lyme arthritis pathogenesis and potential treatment targets.
A $9 million grant from ASAP and The Michael J. Fox Foundation funds an Indiana University-led study on immune cell exhaustion in Parkinson's disease, aiming to develop personalized immunotherapies. The multi-institutional team will map immune system changes to uncover biomarkers and explain disease heterogeneity. Advances in proteomics are also enabling molecular subtyping and precision medicine across neurological disorders.
The global CNS biomarkers market is projected to reach USD 26.13 billion by 2035, amyloid beta therapeutics USD 26.50 billion, and calcineurin inhibitors USD 20.88 billion. AI integration is driving innovation across all three markets.
The EMA’s CHMP recommended approval of Sanofi’s Cenrifki (tolebrutinib) for non-relapsing secondary progressive multiple sclerosis. The phase 3 HERCULES study showed reduced disability progression, while liver injury remains an identified safety risk.
Merck is expanding its AI efforts through partnerships with Google Cloud and Mayo Clinic. The company said it will deploy AI across R&D and use multimodal clinical datasets to support drug discovery and precision medicine.
MSD signed a Google Cloud agreement worth up to $1 billion and entered an AI-focused R&D collaboration with Mayo Clinic. The deals expand AI use in drug discovery, development and broader operations.
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
The FDA approved ScinoPharm Taiwan's glatiramer acetate as the first complex injectable generic for relapsing multiple sclerosis and Sentynl Therapeutics' copper histidinate as the first treatment for pediatric Menkes disease in January 2026. These approvals represent significant advancements in neurological care, with the glatiramer acetate approval following a novel regulatory pathway and the Menkes treatment showing improved survival in early-treated patients.
NeuroTherapia has completed a Phase 2a trial of NTRX-07 in Alzheimer's patients, meeting safety objectives with no treatment-related serious adverse events. Preliminary biomarker analysis shows encouraging results, including MRI findings trending toward stabilization. The oral small molecule targets neuroinflammation and showed positive effects in animal models.
Roche Holding AG shares show potential undervaluation despite strong returns, with DCF models suggesting 59% upside. The pharmaceutical giant trades at P/E ratios below fair value estimates while maintaining solid financial performance and dividend growth. Recent pipeline developments and product innovations support long-term growth prospects.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07616050 |
Evaluation of the Impact of Virtual Park on Training Motivation in Adult Patients |
NOT_YET_RECRUITING | NA |
| NCT07615725 |
Dry Needling in Multiple Sclerosis |
RECRUITING | NA |
| NCT07614321 |
Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis |
RECRUITING | PHASE4 |
| NCT07609719 |
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy |
NOT_YET_RECRUITING | PHASE4 |
| NCT07606742 |
Delivery of a Culturally Tailored Exercise Training Intervention for Hispanics With Multiple Sclerosis |
NOT_YET_RECRUITING | NA |
| NCT07606521 |
A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus |
NOT_YET_RECRUITING | PHASE1 |
| NCT07597668 |
A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT07595081 |
Propionic Acid for Multiple Sclerosis: Safety and Benefits |
COMPLETED | PHASE2/PHASE3 |
| NCT07593911 |
A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases |
NOT_YET_RECRUITING | NA |
| NCT07593807 |
TMS Combined With Virtual Reality and Multidisciplinary Rehabilitation in Multiple Sclerosis |
ACTIVE_NOT_RECRUITING | NA |
